Cencora Inc. closed 4.89% below its 52-week high of $253.27, which the company achieved on November 29th.

CONSHOHOCKEN, Pa., January 08, 2025--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to ...

Cencora Stock Up 1.8 % NYSE COR opened at $240.36 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a fifty-two ...

Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. Cencora Increases Dividend The business also recently announced a quarterly dividend, which was paid on ...

$60,000 of CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Cencora (COR – Research Report) today and set a price target of $285.00. The company’s shares closed yesterday at $236.09.

Drug distributor Cencora raised its annual adjusted profit forecast on Thursday, citing benefits from its $4.4 billion takeover of Retina Consultants of America (RCA) and continued strong performance ...

Please provide your email address to receive an email when new articles are posted on . Cencora completed its acquisition of Retina Consultants of America, according to a press release.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading ...

Cencora Inc. closed $28.56 short of its 52-week high ($253.27), which the company achieved on November 29th.